

P&T Motion History Multiple Sclerosis Drugs

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate	Reiteration of prior motion	Decision
alemtuzumab cladribine dimethyl fumarate diroximel fumarate fingolimod glatiramer acetate interferon β 1a IM, SC interferon β 1b SC peginterferon β 1a SC teriflunomide ocrelizumab ofatumumab ozanimod ponesimod siponimod daclizumab HYP* mitoxantrone* monomethyl fumarate* natalizumab*	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Multiple Sclerosis, I move that alemtuzumab, cladribine, diroximel fumarate, siponimod, daclizumab HYP, mitoxantrone, natalizumab, dimethyl fumarate, teriflunomide, fingolimod, glatiramer, ocrelizumab, monomethyl fumarate, ozanimod, interferon beta 1B SC, peginterferon β 1a SC, interferon beta 1A IM, and interferon beta 1A SC are safe and efficacious. A product that is safe for use during pregnancy should be made available. The MS Drugs cannot be subject to therapeutic interchange in the Washington preferred drug list for the treatment of Multiple Sclerosis. An oral agent should be included in the list of preferred drugs on the PDL.</p> <p>Motion: Lee 2nd: Park</p>	October 19, 2022	Yes Marcotte Schwilke	Yes Flatebo Corsilles	Passed unanimous

Bold = new this update

Grey = not reviewed by OHSU and therefore, not eligible to be preferred

*=drugs not reviewed, but carried forward from previous review

10/20/2022